1061 VALUE OF ELND IN LYMPH NODE NEGATIVE PATIENTS WITH HIGH-RISK LOCALIZED PROSTATE CANCER IS UNCERTAIN
Steven Joniau, Martin Spahn(Universitätsklinikum Würzburg), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Jochen Walz(Institut Paoli-Calmettes), G. Marchioro(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paolo Gontero(Fondazione Ricerca Molinette), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Bülent Akdoğan, Burkhard Kneitz(Universitätsklinikum Würzburg), Francesco Montorsi(Vita-Salute San Raffaele University), A Tizzani(University of Turin), D. Frohneberg(Städtisches Klinikum Karlsruhe), Paul Van Cangh, Pia Bader(Städtisches Klinikum Karlsruhe), Chao‐Yu Hsu(National Chung Hsing University), Markus Graefen(Eppendorf (Germany))
Cited by 0
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
|The Lancet|2005|1.1k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k